- Home
- AVTX vs SABR Comparison
AVTX vs SABR Comparison
Compare AVTX & SABR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AVTX | SABR |
|---|---|---|
| Founded | 2011 | 2006 |
| Country | United States | United States |
| Employees | 33 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Programming Data Processing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 710.1M | 811.2M |
| IPO Year | 2015 | 2014 |
Fundamental Metrics
Financial Performance| Metric | AVTX | SABR |
|---|---|---|
| Price | $12.14 | $1.81 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 14 | 6 |
| Target Price | ★ $44.08 | $2.11 |
| AVG Volume (30 Days) | 959.1K | ★ 5.8M |
| Earning Date | 11-05-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 72.07 | ★ 283.56 |
| EPS | N/A | ★ N/A |
| Revenue | $27,813,137.00 | ★ $3,866,956,000.00 |
| Revenue This Year | N/A | $4.34 |
| Revenue Next Year | N/A | $4.16 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 2312.27 | 7.46 |
| 52 Week Low | $12.51 | $0.81 |
| 52 Week High | $24.27 | $2.50 |
Technical Indicators
Market Signals| Indicator | AVTX | SABR |
|---|---|---|
| Relative Strength Index (RSI) | 22.50 | 33.77 |
| Support Level | N/A | $1.68 |
| Resistance Level | $20.54 | $1.99 |
| Average True Range (ATR) | 0.84 | 0.09 |
| MACD | -0.17 | -0.03 |
| Stochastic Oscillator | 1.24 | 16.04 |
Price Performance
Historical ComparisonAbout AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.
About SABR Sabre Corporation
Sabre holds the number-two air booking volume share in the global distribution system industry. The marketplace segment represented 80% of total 2025 revenue and airline technology solutions 20% of revenue. The company sold its growing hotel IT solutions division to TPG in 2025 for $960 million in net proceeds. Transaction fees, which are mostly tied to volume and not price, account for the bulk of sales and profits.